Yang Vanessa Y, Eaton J Seth, Kiland Julie A, Koch Kelly E, Oikawa Kazuya, Hetzel Scott J, McLellan Gillian J
Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin - Madison, Madison, Wisconsin, USA.
Department of Ophthalmology and Visual Sciences, School of Medicine and Public Health, University of Wisconsin - Madison, Madison, Wisconsin, USA.
Vet Ophthalmol. 2024 Nov 28. doi: 10.1111/vop.13302.
To evaluate the effects of latanoprostene bunod on intraocular pressure (IOP) and pupil diameter (PD) in normal cats and cats with feline congenital glaucoma (FCG).
Five normal and 5 FCG cats.
This masked, controlled crossover study comprised a 1-day Pre-treatment phase followed by two 10-day Treatment phases, each followed by a 10-day Recovery phase. During treatment, all cats received twice daily 0.005% latanoprost (LAT) or 0.024% latanoprostene bunod (LBN) in a randomized eye. Following Recovery, the same eye was treated with the opposite drug. Contralateral eyes served as saline-treated controls. Intraocular pressure and PD measurements were performed three times daily during all study phases. Data were analyzed via constrained longitudinal data analysis models.
Neither drug significantly reduced IOP in normal cats. In FCG cats, statistically significant reductions in mean (95% CI) IOP were observed relative to controls 4 h after LAT and LBN treatment (-5.5 mmHg [-8.4, -2.5], p < .001, -7.2 mmHg [-10.2, -4.3], p < .001, respectively). These differences represented 28.4% and 37.9% IOP reductions, respectively. Mean IOP reduction after 4 h was significantly greater with LBN treatment compared to LAT (-1.8 mmHg [-3.2, -0.4], p = .012). However, these IOP reductions were not considered clinically significant. Both drugs similarly reduced PD in normal and FCG cats.
Transient IOP reduction was observed after topical administration of LAT and LBN in FCG cats; and mean IOP difference was statistically significantly greater in LBN-treated eyes. However, the apparent enhanced hypotensive effect of LBN is not clinically significant.
评估布诺地前列素拉坦前列素对正常猫和患有猫先天性青光眼（FCG）的猫的眼压（IOP）和瞳孔直径（PD）的影响。
5只正常猫和5只FCG猫。
这项双盲、对照交叉研究包括1天的预处理阶段，随后是两个10天的治疗阶段，每个治疗阶段后接着是10天的恢复阶段。在治疗期间，所有猫每天两次在一只随机选择的眼睛中接受0.005%拉坦前列素（LAT）或0.024%布诺地前列素拉坦前列素（LBN）治疗。恢复阶段后，同一只眼睛用另一种药物治疗。对侧眼睛作为生理盐水治疗的对照。在所有研究阶段，每天测量3次眼压和瞳孔直径。数据通过受限纵向数据分析模型进行分析。
两种药物均未使正常猫的眼压显著降低。在FCG猫中，LAT和LBN治疗后4小时相对于对照组，平均（95%CI）眼压有统计学显著降低（分别为-5.5 mmHg [-8.4, -2.5]，p <.001，-7.2 mmHg [-10.2, -4.3]，p <.001）。这些差异分别代表眼压降低了28.4%和37.9%。与LAT相比，LBN治疗4小时后平均眼压降低显著更大（-1.8 mmHg [-3.2, -0.4]，p = 0.012）。然而，这些眼压降低在临床上不被认为具有显著意义。两种药物对正常猫和FCG猫的瞳孔直径降低效果相似。
在FCG猫局部应用LAT和LBN后观察到眼压短暂降低；LBN治疗的眼睛平均眼压差异在统计学上显著更大。然而，LBN明显增强的降压作用在临床上并不显著。
